Helmut Klocker

Helmut Klocker's AcademicInfluence.com Rankings

Helmut Klocker

Earth Sciences

#1929

World Rank

#2669

Historical Rank

Atmospheric Sciences

#145

World Rank

#149

Historical Rank

Geography

#380

World Rank

#559

Historical Rank

earth-sciences Degrees

Download Badge

Earth Sciences

Helmut Klocker's Degrees

PhD Geography University of Vienna
Masters Geography University of Vienna
Bachelors Geography University of Vienna

Why Is Helmut Klocker Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Helmut Klocker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. (1994) (856)
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. (1993) (488)
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. (1998) (456)
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system (1999) (435)
Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomy (2009) (358)
Prostaglandin E2 and Tumor Necrosis Factor α Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production (1997) (323)
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. (2001) (319)
Distant metastases from prostatic carcinoma express androgen receptor protein. (1995) (311)
Rapid signalling by androgen receptor in prostate cancer cells (1999) (279)
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. (1999) (258)
Androgen receptors in prostate cancer. (2003) (250)
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. (2005) (248)
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. (1994) (247)
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. (2012) (222)
Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue (2000) (194)
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. (2010) (194)
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia (2002) (190)
Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity (2011) (174)
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. (2003) (173)
Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. (1999) (167)
Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides (2000) (166)
Androgen Receptor-Ets Protein Interaction Is a Novel Mechanism for Steroid Hormone-mediated Down-modulation of Matrix Metalloproteinase Expression* (1996) (163)
Human renal‐cell carcinoma tissue contains dendritic cells (1996) (157)
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. (2004) (157)
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality (2008) (147)
Expression, structure, and function of androgen receptor in advanced prostatic carcinoma (1998) (145)
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells (2005) (145)
Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia (2000) (140)
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. (2001) (138)
Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. (2012) (134)
DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction (1993) (134)
Bacillus Calmette‐Guérin mycobacteria stimulate human blood dendritic cells (1997) (131)
Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. (2004) (122)
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. (2003) (121)
Androgen receptor – an update of mechanisms of action in prostate cancer (2000) (121)
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy (2017) (115)
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor (2002) (114)
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer (2013) (113)
Androgen receptors in prostate cancer. (2002) (111)
Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer (2004) (109)
Expression and prognostic relevance of annexin A3 in prostate cancer. (2008) (106)
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. (2006) (101)
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group (2011) (101)
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours (2006) (99)
Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic (2001) (97)
Long‐term androgen‐ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells (2004) (97)
Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia (2003) (96)
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. (2004) (94)
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. (2009) (93)
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group (2010) (92)
The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection (2011) (89)
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. (2010) (89)
Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell‐specific markers (1997) (88)
Small G‐protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis (2005) (86)
EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205 (2014) (86)
Modulated expression of WFDC1 during carcinogenesis and cellular senescence (2008) (86)
Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding (1995) (84)
Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance (2018) (81)
Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. (1996) (81)
Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. (2011) (80)
Differential deactivation of human dendritic cells by endotoxin desensitization: role of tumor necrosis factor-alpha and prostaglandin E2. (1998) (79)
In vitro model systems to study androgen receptor signaling in prostate cancer. (2013) (79)
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. (2003) (79)
Targeting the insulin-like growth factor network in cancer therapy (2011) (78)
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. (2009) (78)
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. (2006) (77)
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. (2012) (75)
The Cochaperone Bag-1L Enhances Androgen Receptor Action via Interaction with the NH2-Terminal Region of the Receptor (2003) (74)
Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. (1995) (74)
Genetic alterations in the PI3K pathway in prostate cancer. (2009) (73)
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer (2009) (71)
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. (2006) (71)
A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry (2008) (70)
miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. (2015) (70)
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group (2012) (69)
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer (2013) (69)
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation (2020) (67)
Frequency and clinical significance of transition zone cancer in prostate cancer screening (1997) (66)
Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. (1992) (66)
Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis (2014) (65)
Expression of androgen receptor coregulatory proteins in prostate cancer and stromal‐cell culture models (2000) (64)
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer (2015) (64)
Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3 (2007) (64)
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity (2012) (64)
ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells (2015) (63)
Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk (2005) (63)
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells (2014) (61)
Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. (1999) (61)
The role of oxygen metabolism for the pathological phenotype of Fanconi anemia (1997) (61)
Prostate cancer screening in Tyrol, Austria: experience and results. (2000) (60)
Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer (2010) (59)
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. (2007) (59)
Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. (1996) (58)
Genetic Variation of Genes Involved in Dihydrotestosterone Metabolism and the Risk of Prostate Cancer (2010) (57)
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. (1998) (57)
Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. (1996) (57)
Material-enhanced laser desorption/ionization (MELDI)—A new protein profiling tool utilizing specific carrier materials for time of flight mass spectrometric analysis (2006) (55)
Androgen receptor alterations in prostatic carcinoma (1994) (55)
Expression Level-Dependent Contribution of Glucocorticoid Receptor Domains for Functional Interaction with STAT5 (2001) (54)
Molecular effects of the isoflavonoid genistein in prostate cancer. (2005) (54)
Improvement of specificity in PSA‐based screening by using PSA‐transition zone density and percent free PSA in addition to total PSA levels (1998) (54)
In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. (1997) (53)
Plexin-B1 mutations in prostate cancer (2007) (52)
Prostate carcinoma screening in the county of Tyrol, Austria (1997) (52)
A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study (2016) (52)
Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis (2013) (51)
Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. (2012) (51)
Androgen Receptor Mutations in Carcinoma of the Prostate (2001) (50)
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. (2005) (50)
CAG-repeat expansion in androgen receptor in Kennedy's disease is not a loss of function mutation (1996) (50)
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. (2015) (50)
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk (2012) (49)
Plexin-B1 mutations in prostate cancer. (2008) (49)
Characteristics of prostate cancers detected at low PSA levels (2004) (49)
Screening for prostate cancer: updated experience from the tyrol study (2005) (49)
Isolation of ADP-ribosyltransferase by affinity chromatography. (1986) (48)
Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture (2016) (48)
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008 (2011) (47)
Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection (2011) (47)
Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. (1998) (47)
A role for class 3 semaphorins in prostate cancer (2011) (47)
A mutant androgen receptor from patients with Reifenstein syndrome: identification of the function of a conserved alanine residue in the D box of steroid receptors (1993) (46)
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide (2016) (46)
[Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]. (2002) (46)
MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. (2013) (45)
A single amino acid exchange abolishes dimerization of the androgen receptor and causes Reifenstein syndrome (1995) (45)
Anterior gradient 2 and 3 – two prototype androgen‐responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells (2013) (45)
Expression of the gene for tear lipocalin/von Ebner's gland protein in human prostate (1996) (44)
Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. (2012) (44)
Phytoestrogens derived from Belamcanda chinensis have an antiproliferative effect on prostate cancer cells in vitro. (2004) (44)
Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer (2014) (44)
Androgen Receptor Gene Mutations in Prostate Cancer (1997) (43)
Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions (2018) (43)
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis (2020) (43)
Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas. (1997) (43)
Activation of the androgen receptor by polypeptide growth factors and cellular regulators (2004) (43)
Characterization of normal and malignant prostate tissue by Fourier transform infrared microspectroscopy. (2010) (42)
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity (2001) (41)
Prostate Cancer Screening in Tyrol, Austria: Experience and Results (1999) (41)
Transient expression of a plasmid gene, a tool to study DNA repair in human cells: defect of DNA repair in Cockayne syndrome; one thymine cyclobutane dimer is sufficient to block transcription. (1986) (41)
2127 P2PSA IN COMBINATION WITH TOTAL PSA AND FREE PSA IMPROVES DIAGNOSTIC ACCURACY IN PROSTATE CANCER DETECTION (2010) (41)
Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. (2000) (40)
Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling. (2005) (40)
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer (2013) (40)
Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials (1999) (39)
Serum‐autoantibodies for discovery of prostate cancer specific biomarkers (2012) (39)
Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors (1997) (39)
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer☆ (2013) (39)
Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. (2009) (38)
Validation of Next-Generation Sequencing of Entire Mitochondrial Genomes and the Diversity of Mitochondrial DNA Mutations in Oral Squamous Cell Carcinoma (2015) (38)
Putative Prostate Cancer Risk SNP in an Androgen Receptor‐Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites (2015) (38)
Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: Association with progression and angiogenesis (2004) (38)
Epithelial‐to‐mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia (2014) (38)
Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy (2010) (37)
Estrogens and aspects of prostate disease (2007) (37)
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. (2008) (37)
Identification of genes involved in estrogenic action in the human prostate using microarray analysis. (2004) (37)
Expression and function of androgen receptor in carcinoma of the prostate (2000) (37)
Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. (2002) (36)
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer (2015) (36)
Oxidative phosphorylation and mitochondrial function differ between human prostate tissue and cultured cells (2016) (35)
Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients (2017) (35)
Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group (2014) (35)
Analysis of the immune‐encodrine feedback loop in the avian system and its alteration in chickens with spontaneous autoimmune thyroiditis (1990) (35)
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling (2014) (33)
Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells (2003) (33)
Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens (2002) (33)
Estradiol promotes epithelial‐to‐mesenchymal transition in human benign prostatic epithelial cells (2017) (33)
Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model (2000) (32)
Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y (2013) (31)
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. (2010) (30)
Videoimaging of prostatic stromal‐cell contraction: An in vitro model for studying drug effects (1998) (30)
Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression. (2010) (29)
Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. (2009) (28)
High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance (2015) (28)
Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. (2013) (28)
GPR30 Promotes Prostate Stromal Cell Activation via Suppression of ERα Expression and Its Downstream Signaling Pathway. (2016) (28)
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells (2014) (27)
Mitochondrial Haplogroups and Control Region Polymorphisms Are Not Associated with Prostate Cancer in Middle European Caucasians (2009) (27)
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. (2011) (27)
Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA‐based screening (1999) (27)
DNA repair dependent NAD+ metabolism is impaired in cells from patients with Fanconi's anemia. (1983) (27)
Activation of human dendritic cells by bacillus Calmette-Guerin. (1998) (27)
Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? (1997) (26)
Characterization of two point mutations in the androgen receptor gene of patients with perineoscrotal hypospadia (1993) (26)
Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells (1999) (26)
Electromotive diffusion (EMD) and photodynamic therapy with δ-aminolaevulinic acid (δ-ALA) for superficial bladder cancer (1996) (26)
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment. (2011) (26)
[-2]proPSA is an early marker for prostate cancer aggressiveness (2013) (26)
Formation and sequence analysis of secretoneurin, a neuropeptide derived from secretogranin II, in mammalian, bird, reptile, amphibian and fish brains (1998) (26)
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer—results from an international multicenter study (2017) (25)
Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the Federal State of Tyrol, Austria, 1993–1999 (2001) (25)
The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S (2006) (25)
Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate (2015) (25)
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy (2015) (25)
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A (2010) (24)
Insulin‐like growth factor binding protein‐3 (IGFBP‐3) in the prostate and in prostate cancer: Local production, distribution and secretion pattern indicate a role in stromal‐epithelial interaction (2008) (24)
Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels (1997) (23)
Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome. (1997) (23)
Identification of transcription factors associated with castration‐resistance: Is the serum responsive factor a potential therapeutic target? (2013) (22)
Peptide YY-2 (PYY2) and pancreatic polypeptide-2 (PPY2): species-specific evolution of novel members of the neuropeptide Y gene family. (2000) (22)
Insulin‐Like Growth Factor‐Binding Protein‐5 Enters Vesicular Structures but Not the Nucleus (2007) (22)
Characterization of detergent-solubilized beef liver mitochondrial NAD+ glycohydrolase and its truncated hydrosoluble form. (1996) (22)
The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment (2014) (22)
Reconstruction of the lower urinary tract using autologous muscle transfer and cell seeding: current status and future perspectives (2000) (21)
5-alpha-reductase and the development of the human prostate (2008) (21)
DNA repair in human cells (1987) (21)
Gene therapy strategies in prostate cancer. (2005) (21)
DNA repair in human cells: biochemistry of the hereditary diseases Fanconi's anaemia and Cockayne syndrome. Tenth Fritz-Lipmann lecture. (1986) (21)
Recent developments in molecular action of antihormones (1998) (21)
A synthetic hapten for induction of thymine-dimer-specific antibodies. (1984) (21)
Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts. (2005) (20)
Androgen signal transduction and prostatic carcinoma (2004) (20)
Clinical and biochemical studies in three patients with severe early infantile Cockayne syndrome (1989) (20)
Identification and purification of a bovine liver mitochondrial NAD+‐glycohydrolase (1995) (19)
Quantitative measurement of the androgen receptor in prepuces of boys with and without hypospadias (2008) (19)
Is Eotaxin‐1 a serum and urinary biomarker for prostate cancer detection and recurrence? (2015) (19)
Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells (2018) (19)
Genes differentially expressed in prostate cancer (2004) (18)
Tumor‐infiltrating T lymphocytes from renal‐cell carcinoma express B7‐1 (CD80): T‐Cell expansion by T‐T cell co‐stimulation (1995) (18)
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project. (2001) (18)
Effects of α1‐adrenoceptor antagonists on cultured prostatic smooth muscle cells (2000) (18)
Isolation of a cDNA clone for human NAD+: protein ADP-ribosyltransferase. (1987) (18)
A reliable system for the culture of human prostatic cells (1997) (18)
Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue (1998) (17)
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2. (2007) (17)
Reduced Levels of ATP Synthase Subunit ATP5F1A Correlate with Earlier-Onset Prostate Cancer (2018) (17)
Prostaglandin E2 induces stromal cell-derived factor-1 expression in prostate stromal cells by activating protein kinase A and transcription factor Sp1. (2013) (17)
Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line (1998) (17)
Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer (2020) (17)
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. (2004) (16)
Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. (2003) (16)
Clinical and pathologic features of prostate cancer detected after repeat false‐negative biopsy in a screening population (2004) (16)
Fibroblasts from patients with Fanconi's anemia are not deficient in excision of thymine dimer. (1985) (15)
Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi's anaemia (2004) (15)
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055. (2013) (15)
Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer (2017) (15)
Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot (2015) (14)
Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program (2015) (14)
Genome‐wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays (2006) (14)
Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients (2016) (14)
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo (2015) (14)
Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients (2011) (14)
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer (2020) (14)
PSA‐based screening for prostate cancer in asymptomatic younger males: Pilot study in blood donors (1997) (14)
Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck (2015) (13)
Human APRT deficiency: Indication for multiple origins of the most common Caucasian mutation and detection of a novel type of mutation involving intrastrand‐templated repair (1997) (13)
Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer (2021) (12)
The mean probability of finding cancer in transrectal ultra sound guided prostate biopsy: An update (2004) (12)
Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma. (1995) (12)
The Fritz-Lipmann lecture. DNA repair in human cells. Biochemistry of the hereditary diseases Fanconi's anaemia and Cockayne syndrome. (1987) (12)
Effect of Heat Exposure on Viability and Contractility of Cultured Prostatic Stromal Cells (2000) (12)
Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. (1996) (11)
Ability of PSA‐positive circulating macrophages to detect prostate cancer (2005) (11)
High prevalence of side population in human cancer cell lines (2016) (11)
Dendritic cells for the immunotherapy of renal cell carcinoma. (1997) (11)
Advanced Vibrational Spectroscopic Imaging of Human Tissue in Life Science (2012) (10)
Selective culture conditions for different types of primary human bladder cells (2000) (10)
Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma (2004) (10)
Photodynamic Diagnosis with 5–Aminolevulinic Acid in the Treatment of Secondary Urethral Tumors: First in vitro and in vivo Results (2001) (10)
Antidiabetic drugs influence molecular mechanisms in prostate cancer (2018) (10)
Effects of alpha1-adrenoceptor antagonists on cultured prostatic smooth muscle cells. (2000) (10)
Analysis of a Mutant Androgen Receptor Offers a Treatment Modality in a Patient with Partial Androgen Insensitivity Syndrome (1998) (10)
Succinate Anaplerosis Has an Onco-Driving Potential in Prostate Cancer Cells (2021) (9)
Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies (2020) (9)
Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. (1994) (9)
Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model (2017) (9)
Is real-time PCR the correct method to evaluate the incidence of human papillomavirus in prepuces of asymptomatic boys and men? (2014) (9)
The ONCOTYROL Prostate Cancer Outcome and Policy Model (2014) (9)
Screening for prostate cancer: Updated experience from the Tyrol study (2004) (9)
Fetal Distribution of 5α-Reductase 1 and 5α-Reductase 2, and Their Input on Human Prostate Development (2007) (8)
Androgen Receptor Function in Prostate Cancer Progression (2007) (8)
Development of a cell‐isolation method for human prostatic smooth muscle cells based on cell type‐specific activation of the SM22 gene promoter (2007) (8)
Profiling of Mitochondrial DNA Heteroplasmy in a Prospective Oral Squamous Cell Carcinoma Study (2020) (8)
Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo (2013) (7)
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer (2012) (7)
Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. (2020) (7)
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer (2022) (7)
595: Targeting Androgen Receptor in Hormone-Independent Cancer: Growth Inhibition and Induction of Apoptosis through Down Regulation of the Androgen Receptor with Small Interference RNA (2004) (7)
Influence of blood sampling on protein profiling and pattern analysis using matrix‐assisted laser desorption/ionisation mass spectrometry (2007) (7)
649 LaminA/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway (2012) (7)
A sensitive radioimmuno assay for thymine dimers (2004) (6)
PGE2 modulates the transcriptional activity of ERRa in prostate stromal cells (2014) (6)
An in vitro model for videoimaging of human bladder smooth muscle cell contractions (2000) (6)
Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development. (2007) (6)
ADP-ribosyltransferase is highly conserved: purification and characterization of ADP-ribosyltransferase from a fish and its comparison with the human enzyme (2004) (6)
ADP-ribosyltransferase from Helix pomatia. Purification and characterization. (1987) (6)
Studies on androgen receptor mutations and amplification in human prostate cancer. (2003) (6)
The Impact of Cand1 in Prostate Cancer (2020) (6)
66 Effects of phosphodiesterase inhibitors and nitric oxide donors on cultured human prostatic smooth muscle cells (2004) (6)
Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy (2015) (5)
Tumorigenesis and Neoplastic Progression PIAS 1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p 21 (2012) (5)
Androgen receptor mutations in prostate cancer (1998) (4)
Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. (2021) (4)
Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer (2021) (4)
Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy (2021) (4)
Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50. (2014) (4)
PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer. (2015) (4)
Adverse pathological findings in needle biopsy gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy. (2012) (4)
Novel Experimental Therapeutic Approaches for Prostate Cancer (2005) (3)
The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer (2020) (3)
473: Tyrolean Screening Study: Update 2005 - Stage Migration and Decrease of Mortality (2006) (3)
Androgen Receptor Structure and Prostate Cancer (1996) (3)
IMAGING OF PROSTATE TISSUE SECTIONS BY MALDI PROTEIN MASS SPECTROMETRY – TISVIS, A TOOL FOR THE VISUAL DATA PROCESSING (2008) (3)
Curbing tobacco's toll starts with the professionals: World No Tobacco Day (2005) (3)
Cytogenetics of prostate cancer (1994) (3)
Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature (2019) (3)
Prostate-Specific Antigen Testing in Tyrol , Austria : Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data (2012) (3)
Aging and DNA Repair (1990) (3)
KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients (2021) (2)
A workflow for preprocessing and proteomic biomarker identification on mass-spectrometry data (2010) (2)
Retraction notice to “Prostate cancer screening in the Tyrol, Austria: experience and results” [Eur J Cancer 36 (2000) 1322–1335]. (2012) (2)
Repair rate in human fibroblasts measured by thymine dimer excorporation (2004) (2)
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer (2022) (2)
600Prostate cancer detection rates in the low and intermediate PSA range (2005) (2)
Effects of cycling and rowing on serum concentrations of prostate‐specific antigen: A randomized study of 101 male subjects (2022) (2)
985 ACCESS [-2]PROPSA AND BECKMAN COULTER PROSTATE HEALTH INDEX (PHI) AND EARLY DETECTION OF AGGRESSIVE PROSTATE CANCERS (2010) (2)
599Prostate cancer mortality following introduction of prostate specific antigen (PSA) mass screening in the federal state of tyrol, Austria: Follow-up until 2003 (2005) (2)
[Clinical consequences of androgen receptor malfunction]. (2004) (2)
Long-term biochemical evaluation of the androgen receptor pathway in males with disorders of sex development (2011) (2)
Mitochondrial function and mitochondrial heteroplasmy levels differ between benign and malignant prostate tissue. (2016) (1)
77 Intracellular PSA staining of circulating macrophages: A new method for discrimination between benign and malignant prostatic disease (2004) (1)
1197 THE WORST CANCERS SEND EARLY PSA SIGNALS THAT WOULD ALLOW EARLY DETECTION IF MONITORING FOCUSED ON INCREASING PSA (2011) (1)
Diagnostic utility of total PSA, free PSA and PSA density at total PSA levels below 4 ng/ml compared to total PSA levels between 4.1 and 10.0 ng/ml in an early prostate cancer detection program (2003) (1)
The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer (2022) (1)
Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis (2013) (1)
256: Prostate Cancer Detection Rates in the Low and Intermediate PSA Range (2005) (1)
424: Overexpression of the Anti-Apoptotic Protein MCL-1 is an Early Event in Prostate Cancer (2004) (1)
1086: Ultrasound-Mediated Microbubble Destruction to Direct Antisense Molecules into Prostate Cancer Cells in Vitro (2004) (1)
Benign prostatic hyperplasia ( BPH ) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E 2 (2007) (1)
Implications of Standardized Uptake Values of Oral Squamous Cell Carcinoma in PET-CT on Prognosis, Tumor Characteristics and Mitochondrial DNA Heteroplasmy (2021) (1)
Expression of the androgen receptor coactivator Bag1 is upregulated in prostate cancer (2003) (1)
67 The flavonoid apigenin inhibits the proliferation of prostatic stromal cells by cell cycle arrest in G1/S (2004) (1)
Pathway in Prostate Cancer Cell Lines Kinase A Activator on the Mitogen-activated Protein Kinase Action of EGF , Insulin-like Growth Factor I , and a Protein Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Updated (1998) (1)
Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays (2005) (1)
A Concept of a MIABIS based Register of Biosample Collections at the Medical University of Innsbruck (2014) (1)
Age-specific serum levels of complexed PSA (CPSA) for prostate cancer screening (2003) (1)
154: Integration of TPSA and High-Throughput Mass Spectrometry Data Improves Prostate Cancer Prediction (2007) (1)
ANDROGENS, PROTEIN KINASE A ACTIVATORS, AND GROWTH FACTORS USE DIFFERENT MECHANISMS TO ACTIVATE THE ANDROGEN RECEPTOR (1999) (1)
Further Insíghts into Endocrine Disease. Oestrogens and theProstate Gland (2006) (1)
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling (2014) (1)
THE USE OF -2proPSA AND BPSA IN PROSTATE CANCER DETECTION: EXTERNAL CROSS-VALIDATION OF A PREDICTIVE MODEL (2008) (1)
1426: Effects of Estrogen on Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Prostate Stromal Cells (2005) (1)
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening. (2014) (1)
THE TYROL PROSTATE CANCER DEMONSTRATION PROJECT (1988 - 2007): MORBIDITY AND MORTALITY (2008) (1)
545 DHT Regulates Serum Response Factor Transcription Activity in Castrate-resistant Prostate Cancer Cell Lines (2012) (1)
Matrix-Assisted Laser Desorption-Ionization Imaging Mass Spectrometry for Direct Tissue Analysis (2011) (1)
305 Differential metabolic effects of medium-chain triglycerides and omega-3 fatty acids in benign and malignant prostate cells – evidence for a ketogenic diet as adjuvant therapy for prostate cancer (2014) (1)
Identification of genes involved in mechanism of estrogenic action in the human prostate using microarray analysis (2003) (1)
Analysis and Visualization of Spatial Proteomic Data for Tissue Characterization (2008) (1)
Prostatitis and Urethritis (1999) (1)
Fibroblast Growth Factors and Their Receptors in Metastases of Prostate and Other Urological Cancers (2001) (1)
635 [-2] PROPSA IS AN EARLY MARKER FOR PROSTATE CANCER AGGRESSIVENESS (2011) (1)
Poly-ADP-ribosylation is not required for excision of a DNA damage (1983) (1)
616Detection of prostate cancer using serum proteomics pattern in a histological confirmed population (2005) (1)
Prostatitis and Urethritis (1999) (1)
[The androgen receptor. New aspects in intersexuality patients]. (1993) (1)
Androgen receptor regulation by physiological concentration of the isoflavonoid genistein in LNCaP prostate cancer cells is mediated by estrogen receptor β (2003) (1)
1756: The Tyrol Prostate Cancer Demonstration Project (1988-2006): Early Detection, Treatment, Outcome, Incidence and Mortality (2007) (1)
747 THE WORST CANCERS SEND EARLY PSA SIGNALS THAT WOULD ALLOW EARLY DETECTION IF MONITORING FOCUSED ON INCREASING PSA (2011) (1)
Thrombospondin 1 and cathepsin D improve the detection of high-grade prostate cancer and reduce the number of unnecessary prostate biopsies (2018) (1)
Ligand-Dependent and Independent Activation of the Androgen Receptor and Implications for Therapy (2004) (1)
PROLIFERATION AND PHENOTYPIC MODULATION OF STROMAL CELLS IN RELATION TO THE EXPRESSION OF ERα IN BPH (2008) (1)
Identifying Biologically Meaningful Groups of Genes in the Androgen Receptor Network (2013) (1)
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor (2007) (1)
1491 IMMUNOHISTOCHEMICAL ERG STATUS IS NOT PREDICTIVE FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY WITH POSITIVE SURGICAL MARGIN (2013) (0)
COMBINED TARGETING OF ANDROGEN RECEPTOR AND PROTEIN KINASE A SIGNALLING PATHWAYS INCREASES INHIBITION OF PROSTATE TUMOUR GROWTH (2008) (0)
First identification and validation of prostate cancer specific tumor endothelial cell markers by multi-omic profiling (2021) (0)
Endothelin activates the mitogen-activated protein kinase pathway through endothelin receptor B in prostate stromal cells (2002) (0)
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis (2020) (0)
Vol. 35, 1999 (1999) (0)
12th Congress of the European Society for Urological Oncology and Endocrinology (ESUOE) March 6–8, 1997, Essen, Germany (2004) (0)
CORRELATION OF TOTAL PSA WITH PATHOLOGIC STAGE AND TUMOR VOLUME IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY FOLLOWING PSA SCREENING WITH LOW PSA CUTOFF LEVELS (1999) (0)
Vol. 35, 1999 (1999) (0)
Mitochondrial complex I gene mutations drive metabolic reprogramming in prostate cancer (2019) (0)
Subject Index Vol. 35, 1999 (1999) (0)
PSA-VELOCITY DEPENDS ON PATHOLOGICAL STAGE AND GLEASON SCORE, EVEN AFTER BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY (2006) (0)
Natural dihydrochalcones as novel AKR1C3 inhibitors in therapy-resistant prostate cancer (2019) (0)
Subject Index Vol. 35, 1999 (1999) (0)
THE IMPACT OF INTERNAL STANDARDS IN MASS SPECTROMETRY USED FOR PATTERN ANALYSIS OF PROSTATE CANCER SERUM (2006) (0)
CORRELATION BETWEEN PREOPERATIVE PREDICTORS OBTAINED AT PSA-BASED SCREENING AND PATHOLOGIC FEATURES IN RADICAL PROSTATECTOMY SPECIMENS (1999) (0)
934 P2X 3 RECEPTOR-EXPRESSION IN FETAL AND INFANT BLADDERS - THE BASIS FOR A NEW THERAPEUTIC CONCEPT FOR OVERACTIVE BLADDERS IN CHILDREN (2007) (0)
ACQUISITION OF AGONISTIC PROPERTIES OF BICALUTAMIDE IS ASSOCIATED WITH PROSTATE TUMOR PROGRESSION IN A NEW MODEL SYSTEM (1999) (0)
1424: Development of a Cell Isolation Method for Human Prostatic Smooth Muscle Cells Based on Cell type Specific Activation of the SM22 Gene Promoter (2005) (0)
395 COMPLICATION RATES OF 7074 TRANSRECTAL, ULTRASOUND (TRUS) GUIDED BIOPSIES OF THE PROSTATE: RESULTS FROM THE TYROL PSA SCREENING PROJECT (2007) (0)
750 GENE EXPRESSION ANALYSIS OF ETS TRANSCRIPTION FACTOR FAMILY GENES AND ANDROGEN RECEPTOR IN LASER CAPTURE MICRODISSECTED HUMAN PROSTATE CANCER TISSUE (2010) (0)
113 ANNEXIN A3 QUANTIFICATION FROM SUPERNATANTS OF URINE AFTER DRE PROVIDES A NOVEL AND CLINICALLY EASY AVAILABLE BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF PROSTATE CANCER (2007) (0)
410 LAMIN A/C IS A POTENTIAL DISCRIMINATORY BIOMARKER OF LOW AND HIGH GRADE PROSTATE CANCER (2010) (0)
PROSTATE CANCER-MOLECULAR BIOLOGY, HORMONES AND GROWTH FACTORS (1996) (0)
Supplementary figure 1 PIAS1 (2013) (0)
Visual Feature Selection in Biological Time-Series for Mass Spectrometry based Biomarker Discovery (2007) (0)
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer (2022) (0)
1428: Influence of Prostatic Epithelium on Proliferation and Differentiation of Stromal Cells (2005) (0)
INFLUENCE OF BLOOD SAMPLING ON PROTEIN PROFILING AND PATTERN ANALYSIS USING MALDI MASS SPECTROMETRY (2006) (0)
309 Therapeutic efficacy of the Y-90 labeled antibody 19G9, targeting a novel protein RG-1, expressed in metastatic prostate cancer (2004) (0)
436 INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3 IN URINE - ORIGINATING IN PART FROM THE PROSTATE GLAND BUT NO CORRELATION WITH PROSTATE CANCER (2007) (0)
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation (2020) (0)
G-protein RhoE is underexpressed in prostate cancer and induces G1 arrest through down-regulation of cyclin D2 (2003) (0)
450 Measurement of intracellular PSA-levels vs. extra-cellular PSA-levels in peripher macrophages. A new approach to the noninvasive diagnosis of prostatic cancer (2004) (0)
617 STEROID HORMONES REGULATION OF METASTASIS-ASSOCIATED CHAPERONE PROTEINS AGR2 AND AGR3 IN PROSTATE CANCER CELLS (2011) (0)
Clinical effects of androgen receptors (2004) (0)
Cancer-associated fibroblast heterogeneity within the prostate cancer stromal microenvironment (2018) (0)
2503 Hypermethylation of a specific area in the TERT promoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy (2015) (0)
431 A NEW MOLECULAR MECHANISM OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3 IN PROSTATE CANCER CELLS (2007) (0)
886The expression of transcription factor ATF3 in the human prostate and its regulation by androgen in prostate cancer cells (2005) (0)
Correlation of prostate volume (PV), transition zone of the prostate (TZV), total serum PSA (T-PSA), free PSA percent (F-PSA) and complexed PSA (C-PSA) with age in a asymtomatic screening population (2003) (0)
Genistein modulation of intricate signaling pathways underlying PC3 cells treatment (2008) (0)
Inhibition of NADPH oxidase 4 attenuates stromal activation associated with prostate cancer (2016) (0)
Abstract 4599: Negative feedback loop between serum response factor and androgen receptor in castrate-resistant prostate cancer (2014) (0)
683 ESTRADIOL PROMOTES THE INVASIVE POTENCY OF PROSTATE CANCER CELLS IN A PARACRINE MANNER THROUGH STIMULATION OF PROSTATIC STROMAL CELLS (2010) (0)
86 Overexpression of the anti-apoptotic protein MCL-1 is an early event in prostate cancer (2004) (0)
MULTI-COLOUR STAINING AND TISSUEFAXS ANALYSIS FOR VALIDATION OF PROSTATE CANCER TISSUE MARKERS AND THERAPY TARGETS EXPRESSION (2006) (0)
Abstract 3183: Targeting a myofibroblastic prostate cancer-associated fibroblast subtype through pharmacological inhibition of NADPH oxidase 4 (2022) (0)
Cand1 in prostate cancer and its implication in therapy resistance to enzalutamide (2019) (0)
Effects of systemic glucocorticoid administration on stromal and epithelial GR signaling with consequences for prostate cancer progression. (2019) (0)
EXPRESSION AND LOCALISATION OF PROTEINS OF THE IGF AXIS IN THE PROSTATE AND PROSTATE CANCER (2006) (0)
[Control mechanisms of tonus of smooth muscle of the prostate and their potential significance for pharmacotherapy of benign prostatic syndrome]. (2007) (0)
Androgen Receptor Crosstalk with Cell Signaling Pathways (2003) (0)
735 THE IMPACT OF INSULIN AND ITS RECEPTORS ON IGF TARGETING THERAPIES IN PROSTATE CANCER (2011) (0)
The role of HIF-1 in the apoptotic response of prostate cancer cells to hypoxia (2003) (0)
Abstract 3549: miRNAs and androgen receptor interplay in prostate cancer (2014) (0)
Review Article ANDROGEN RECEPTORS IN PROSTATE CANCER (2003) (0)
607: Low PSA Levels Cannot Rule out Prostate Cancer:Prostate Cancer Detection Rates with Respect to PSA Levels Results from a PSA Based Screening Cohort (2007) (0)
Risk-modelling of prostate carcinoma using anti-nutrient serum Anti-Food Immunoglobulines (AFIG) (2022) (0)
Contents Vol. 94, 2015 (2015) (0)
581: Measurement of Intracellular vs Extracellular PSA-Levels in Peripheral Macrophages (2004) (0)
PSA-BASED SCREENING WITH VERY LOW PSA CUTOFF VALUES: CORRELATION BETWEEN AGE AND CLINICAL AND PATHOLOGIC FEATURES IN THE 40-59 AGE GROUP (1999) (0)
248 Up-regulation of androgen receptor expression in enzalutamide-resistant prostate cancer cells (2016) (0)
224 HPV detection and genotyping in non-muscle invasive bladder cancer by single-step PCR (HPV-L1) and reverse line blot (RLB) hybridization assay (2015) (0)
Abstract LB-278: Transcriptomic profiling of castrate resistant prostate cancer cells: identification of transcription factors associated with androgen resistance (2011) (0)
573 Targeting androgen receptor in hormone-independent cancer: Growth inhibition and induction of apoptosis through down regulation of the androgen receptor with small interference RNA (2004) (0)
IGFBP-3 INHIBITS PROSTATE TUMOUR CELL ADHESION, MIGRATION AND INVASION (2008) (0)
The influence of RAS-inhibitors on prostate cancer aggressiveness (2022) (0)
1580: PSA-Velocity as a Tool to Identify Organ Confined Prostate Cancers in a Screening Population (2006) (0)
The role of the chemokine receptor CXCR4 and its ligand CXCL12 in prostate cancer (2003) (0)
Abstract A38: Maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer (2012) (0)
Regulation of steroid receptor expression and proliferation in prostate cancer by genistein and other flavonoids (2006) (0)
Prostate tumor growth is driven by increased cholesterol and steroid production (2020) (0)
The mean probability of finding cancer in transrectal ultra sound guided prostate biopsy: An update. (2004) (0)
1456: The Flavonoid Apigenin Inhibits the Proliferation of Prostatic Stromal Cells by Cell Cycle Arrest in G1/S (2005) (0)
A MutantAndrogen Receptor fromPatients withReifenstein Syndrome: Identification oftheFunction ofa Conserved Alanine Residue intheD BoxofSteroid Receptors (1993) (0)
Marker sequences for prostate inflammatory diseases, prostate cancer and their use (2008) (0)
cDNA MICROARRAYS EXPERIMENTAL DESIGN AND GENE EXPRESSION ANALYSIS OF GENISTEIN TREATED HUMAN PROSTATE CANCR CELLS PC-3 (2007) (0)
Regulation of genes involved in cell cylce regulation in androgen-sensitive and androgen-independent LNCaP prostate cancer cells subjected to androgen receptor protein down regulation (2003) (0)
PROTEIN PROFILING WITH WHOLE PROSTATIC TISSUES BY MALDI (2006) (0)
Antisense approaches for the treatment of prostate cancer (2001) (0)
Abstract B62: Protein inhibitor of activated STAT1 (PIAS1) is expressed in prostate cancer and stimulates cellular proliferation through inhibition of p21 (2012) (0)
267: MELDI-MS - New Approach for Protein Profiling in Prostate Cancer (2006) (0)
Upregulation of cholesterol and steroid biosynthesis pathways in prostate cancer cells is associated with diminished response to enzalutamide in a 3-dimensional spheroid co-culture model (2018) (0)
STAGE MIGRATION: RESULTS OF A FIVE-YEAR PSA-BASED SCREENING PROGRAM (1999) (0)
Complexed prostate specific antigen combined with clinical parameters enhances prediction of prostate cancer (2003) (0)
Endocrine-Related Cancer ( 2002 ) 9 155 – 170 Androgen receptors in prostate cancer (2002) (0)
836 STEROID HORMONES REGULATION OF METASTASIS- ASSOCIATED CHAPERONE PROTEINS AGR2 AND AGR3 IN PROSTATE CANCER CELLS (2011) (0)
Staging and histopathology of prostate cancers with total PSA levels below 3.99 NG/ML (2002) (0)
Androgen receptor coactivator CBP is down-regulated by androgens in prostate cancer cells (2003) (0)
576 The expression of transcription factor ATF3 in the human prostate and its regulation after decrease of androgen receptor by siRNA in long-term androgen-ablated LNCAP prostate cancer cells (2004) (0)
PO-324 Detection of high-risk prostate cancer biomarkers by RNA sequencing and qPCR method (2018) (0)
Abstract A37: Low-density protein array reveals inflammation associated serum-autoantibody profile in prostate cancer. (2012) (0)
RETRACTED: Prostate cancer screening in the Tyrol, Austria (2000) (0)
Personalized prostate cancer screening accounting for individual risk factors and preferences (2016) (0)
CORRELATION OF PSA-VELOCITY WITH TUMOUR-STAGE AND GLEASON SCORE IN A SCREENING POPULATION (2006) (0)
579: Androgen Receptor Regulation by Physiological Concentration of the Isoflavonoid Genistein in LNCAP Prostate Cancer Cells is Mediated by Estrogen Receptor ß (2004) (0)
126 EXPONENTIAL PSA TRENDS PREDICT THE RISK OF HIGH GLEASON CANCER TWO YEARS INTO THE FUTURE FOR A SCREENING POPULATION (2011) (0)
Switch to succinate-mediated mitochondrial respiration associated with HIF-1[alpha] stabilization in PTEN negative prostate cancer cells (2016) (0)
MP37-11 TERT PROMOTER METHYLATION IS A PAN-CANCER BIOMARKER WITH PROGNOSTIC SIGNIFICANCE IN PROSTATE CANCER PATIENTS (2015) (0)
Molecular Diagnostics of Diseases with Androgen Receptor Mutations (1999) (0)
1109: The Inhibitory G-Protein Rhoe is Underexpressed in Prostate Cancer and Induces Cell Cycle Arrest and Apoptosis (2004) (0)
Abstract B49: LaminA/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration, and invasion through the PI3K/AKT/PTEN pathway (2012) (0)
744 A PREOPERATIVE SERUM BIOMARKER PANEL TO IDENTIFY PATIENTS WITH PROSTATE CANCER AT HIGH RISK OF BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (2011) (0)
611Macrophage PSA levels is predictive for prostate cancer in patients with multiple prostate biopsies for suspect serum total PSA levels (2005) (0)
Pharmacological inhibition of NADPH oxidase 4 abrogates stromal activation associated with prostate cancer (2018) (0)
2153 PSAV FROM LONG-TERM, CONSISTENT PSA TRENDS HELPS IDENTIFY THE WORST CANCERS AND DISTINGUISH THEM FROM THE BEST CANCERS – RESULTS FROM THE TYROL CANCER DEMONSTRATION PROJECT (2010) (0)
A sensitive assay for thymine dimers (1982) (0)
Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Action of EGF , Insulin-like Growth Factor I , and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines 1 (1998) (0)
7 PSA-Isoforms-Velocity. Evaluation of a novel approach in the early diagnosis of prostate cancer. Results from the Tyrol PSA screening project (2013) (0)
STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway (2022) (0)
880 Prevalence of PSA recurrence after radical prostatectomy of localised prostate cancer with positive resection margin depends on the pathological stage and on the Gleason score: Long term results of a retrospective, single center study (2012) (0)
Role of mitochondrial dynamics in tumorigenic potential and docetaxel resistance in prostate cancer (2022) (0)
THE CENTRAL ROLE OF EGF RECEPTOR BLOCKADE IN THE INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS: IMPLICATIONS FOR PROSTATE CANCER THERAPY (1999) (0)
Tumorigenesis and Neoplastic Progression Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200 c and miR-205 (2012) (0)
Supplementary figure 3 PIAS1 (2013) (0)
ENDOTHELIN-1 BUT NOT ENDOTHELIN-3 INDUCES CONTRACTION OF CULTURED PROSTATIC SMOOTH MUSCLE CELLS (1999) (0)
512 A PROSTATE CANCER DIAGNOSTIC TOOL BASED ON HIGH-THROUGHPUT MS SERUM PROTEIN PROFILES (2007) (0)
7 Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European caucasians (2010) (0)
In memoriam of Georg Bartsch, MD, Professor of urology (1942–2012) (2012) (0)
The detection rate of clinically insignificant prostate cancer is not increased by PSA-based mass screening: analysis of low-volume, highly differentiated prostate cancers following TURP (2002) (0)
1728 EARLY DETECTION OF PROSTATE CANCER (TYROL PROSTATE CANCER DEMONSTRATION PROJECT 1988-2008): 20 YEARS EXPERIENCE (2010) (0)
230: The Expression of Transcription Factor ATF3 in the Human Prostate and its Regulation by Androgen in Prostate Cancer Cells (2005) (0)
398 Different history of total PSA before biopsy in men with BPH and prostate cancer (2004) (0)
609: Effects of Sirna and Phytoestrogen Treatments on the Expression of Genes Regulated through the Androgen Receptor of Lncap Prostate Cancer Cells (2004) (0)
DYNAMIC CHANGES OF STROMAL CELL IN THE PROCESS OF ESTROGEN/ANDROGEN INDUCED PROSTATIC STROMAL HYPERPLASIA IN CASTRATED RATS (2009) (0)
1018 LOW PSA LEVELS CANNOT RULE OUT PROSTATE CANCER: PROSTATE CANCER DETECTION RATES WITH RESPECT TO PSA LEVELS (2007) (0)
ANTISENSE ANDROGEN RECEPTOR OLIGODEOXY-NUCLEOTIDES: A NEW METHOD FOR INHIBITION OF PROSTATE TUMOR CELL GROWTH (1999) (0)
Prostate Stem Cell Antigen: Its Possible Role During Fetal Development and Later on in Life (2007) (0)
ESTROGEN PROMOTES PROSTATE STROMAL CELLS PROLIFERATION THROUGH RAPID ACTIVATION OF ERK MEDIATED BY ERα (2008) (0)
Comprehensive multi-omic profiling of tumor endothelial cells of prostate tissue (2019) (0)
1420 TANSHINONE IIA INHIBITS ESTROGEN/ANDROGEN INDUCED PROSTATIC STROMAL HYPERPLASIA (2010) (0)
741 PROLIFERATION AND GLUCOSE METABOLISM IS INFLUENCED DIFFERENTLY BY THE INSULIN-LIKE-GROWTH-FACTOR (IGF)/INSULIN AXIS IN PROSTATE CANCER & BENIGN PROSTATE CELLS (2011) (0)
Abstract A26: Changes in gene expression in ERG-rearrangement positive prostate cancer are related to signaling, adhesion, and defense response (2012) (0)
APPLICATION NOTE Material-Enhanced Laser Desorption/Ionization (MELDI)—A New Protein Profiling Tool Utilizing Specific Carrier Materials for Time of Flight Mass Spectrometric Analysis (2006) (0)
1963: Complication Rates of 7074 Transrectal, Ultrasound (TRUS) Guided Biopsies of the Prostate: Results from the Tyrol PSA Screening Project (2007) (0)
Regulation of hAG-2 and hAG-3 transcripts inprostate cancer (2007) (0)
Purification and characterization (2005) (0)
Diminished response of prostate cancer cells to antiandrogens upon co-culture with cancer-associated fibroblasts as shown in a 3-dimensional prostate cancer epithelial-stromal organoid model (2016) (0)
236 ALPHAVBETA3 INTEGRIN -A POSSIBLE CANDIDATE TO TARGET MICROBUBBLE CONTRAST AGENTS TO PROSTATE TUMORS (2007) (0)
Abstract 2201: A novel androgen receptor regulatory loop: Posttranscriptional androgen receptor regulation through Midline 1 ribonuclear protein complex (2012) (0)
469: Positive Margins in Radical Prostatectomy and Biochemical Recurrence: not as Easy as Yes or No! (2007) (0)
Prostate-Specific Antigen Testing in Tyrol , Austria : Prostate Cancer Mortality Reduction (2012) (0)
803 Immunohistochemical ERG status is not predictive for biochemical recurrence after radical prostatectomy with positive surgical margin (2013) (0)
935 A novel androgen receptor regulatory loop: Posttranscriptional androgen receptor regulation through the midline 1 ribonuclear protein complex (2012) (0)
1614: Correlation between Gleason Score of Needle Biopsies and Gleason Score of Radical Prostatectomy: 12 Years Experience (2005) (0)
1425: Annexin A3 Quantification from Supernatants of Urine After Dre Provides a Novel and Clinically Easy Available Biomarker for the Non-Invasive Diagnosis of Prostate Cancer (2007) (0)
13th Congress of the European Society for Urological Oncology and Endocrinology (1998) (0)
DNA Repair in Human Cells: Molecular Cloning of cDNAS Coding for Enzymes Related to Repair (1988) (0)
608Complication rates of 6272 transrectal, ultrasound (TRUS) guided biopsies of the prostate: Results from the tyrol PSA screening study (2005) (0)
422 TERT promoter methylation is a pan-cancer biomarker with prognostic significance in prostate cancer patients (2015) (0)
Paracrine and autocrine stimulation in prostate cancer (1997) (0)
536: Prostate Cancer Mortality Following Introduction of Prostate Specific Antigen (PSA) Mass Screening in the Federal State of Tyrol, Austria: Follow-Up Until 2003 (2005) (0)
Abstract 1125: The insulin-like growth factor (IGF) axis is involved in normal prostate differentiation and downregulated in local prostate cancer (2011) (0)
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells (2014) (0)
127 AUTO-ANTIBODY BASED BIOMARKERS FOR NON-INVASIVE MOLECULAR DIAGNOSTICS OF PROSTATE CANCER (2011) (0)
1352: Estradiol Enhances Expression of Smooth Muscle Cellspecific Markers in Prostatic Stromal Cells through Paracrine Stimulation of Transforming Growth Factor Beta from Prostatic Epithelial Cell Line BPH-1 (2007) (0)
485: PSA-Velocity Increases Continuously in the Years Prior to Diagnosis of Prostate Cancer (2006) (0)
CLINICALLY ACHIEVABLE DOSE OF LOVASTATIN IN COMBINATION WITH SIRNA-MEDIATED KNOCKDOWN OF ANDROGEN RECEPTOR INDUCES STRONG GROWTH-INHIBITORY EFFECTS ON LNCAP PROSTATE CANCER CELLS (2008) (0)
578 Androgen receptor regulation by physiological concentration of the isoflavonoid genistein in LNCAP prostate cancer cells is mediated by estrogen receptor β (2004) (0)
Abstracts 1st World Congress on Urological Research organized by the European Society for Urological Oncology and Endocrinology (ESUOE) and the American Society for Basic Urological Research (SBUR) September 1–3, 1995, Rotterdam, The Netherlands (2004) (0)
Differences in the expression of apoptosis-related proteins in LNCAP and long-term androgen-ablated LNCAP prostate cancer cells (2002) (0)
Low Cand1 expression is associated with reduced prostate cancer growth (2018) (0)
Shift of mitochondrial oxidative phosphorylation is associated with mtDNA mutational load in primary prostate cancer tissue (2018) (0)
829 Improvement of efficacy of insulin-like growth-factor receptor (IGF)-targeting-therapies by co-targeting insulin receptor A in prostate cancer (2013) (0)
509 INTEGRATION OF TPSAAND HIGH-THROUGHPUT MASS SPECTROMETRY DATA IMPROVES PROSTATE CANCER PREDICTION (2007) (0)
Combined targeting of cholesterol and steroid biosynthesis effectively inhibits enzalutamide resistant prostate cancer cells and 3-dimensional spheroid growth (2019) (0)
A Sensitive Radioimmuno Assay for Thymine (1982) (0)
Dendritic Cells for the Immunotherapy of Renal Cell Carcinoma (1998) (0)
309 NMR based metabolic analysis of prostate cancer and non-cancerous prostate epithelial cells: The impact of IGF1R and INSR signaling (2014) (0)
1480: PSA does not Discover Low Stage and Low Grade Prostate Cancers (2006) (0)
360 The inhibitory G-protein rhoe is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis (2004) (0)
2223 ERG GENE REARRANGEMENT IS MORE FREQUENT IN EARLY-ONSET PROSTATE CANCER AND IS ASSOCIATED WITH LOWER PSA SERUM LEVELS IN YOUNGER PATIENTS IN A PSA SCREENING COHORT (2012) (0)
Clinically insignificant improvement of prostate cancer prediction by addition of sex steroid hormones and SHBG serum levels to serum PSA, fPSA%, and age in a screening setting (2012) (0)
417: Macrophage PSA Levels is Predictive for Prostate Cancer in Patients with Multiple Prostate Biopsies for Suspect Serum Total PSA Levels (2005) (0)
1733: Transurethral Prostatectomy: Long Term Morbidity after a follow up of 15 Years (2007) (0)
CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF PROSTATE CANCER IN MEN YOUNGER THAN 45 YEARS: RESULTS FROM THE TYROL PSA SCREENING PROJECT (2008) (0)
525 No effect of antidiabetic drugs on prostate cancer aggressiveness and progression (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Helmut Klocker?

Helmut Klocker is affiliated with the following schools:

University of Innsbruck
Capital Medical University
University of Oxford
University of Minnesota
Medical University of Innsbruck
University of Toronto
University of Vienna

Helmut Klocker's Academic­Influence.com Rankings

Helmut Klocker's Degrees

Why Is Helmut Klocker Influential?

Helmut Klocker's Published Works

Published Works

What Schools Are Affiliated With Helmut Klocker?

Helmut Klocker's AcademicInfluence.com Rankings